Decrease of Resolvin D1 and E1 in Patients with Chronic Epilepsy, Implicating Dysfunction of Neuroinflammation Resolution
Journal of Inflammation Research · 2025-06 · Volume 18 · 8541-8551
DOI: 10.2147/jir.s521679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inflammation Research, 2025-06. Verfasst von Hanli Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Anhui Medical College, Hefei, People's Republic of China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
Inflammation resolution is mediated by specialized pro-resolving lipid mediators (SPMs). It's of high interest to understand the alterations of SPMs in chronic epilepsy.
Methods
Sixty-five patients with chronic epilepsy, 43 healthy controls and 43 patients with non-inflammatory neurological disorders were enrolled in this study. Plasma and cerebrospinal fluid (CSF) levels of SPMs were measured using liquid chromatography-tandem mass spectrometry (LC-MS-MS). Moreover, Resolvin D1 (RvD1) and resolvin E1 (RvE1), as well as pro-inflammatory factors were analyzed by enzyme-linked immunosorbent assay (ELISA).
Results
LC-MS-MS found several lipid mediators were altered, especially plasma (P = 0.014) and CSF (P = 0.010) RvE1 levels were decreased in patients with chronic epilepsy. Furthermore, ELISA results showed that in plasma and CSF, RvD1 and RvE1 levels were both lower in patients with chronic epilepsy, while pro-inflammatory factors were higher than in controls. Moreover, plasma RvE1 level was independently negatively associated with the National Hospital Seizure Severity Scale scores (Β = -0.00636, P < 0.001). While plasma RvD1 level was correlated with Mini-Mental State Examination scores (R = 0.284, P = 0.022).
Conclusion
This study demonstrated decreased levels of RvD1 and RvE1 both in plasma and CSF in patients with chronic epilepsy, suggesting impaired resolution of inflammation in chronic epilepsy. Targeting RvD1 and RvE1 may be a novel direction worthy of further research in the treatment of chronic epilepsy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Clinical Medicine, Anhui Medical College, Hefei, People's Republic of China.
- Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
- Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
- Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, People's Republic of China.
ORCID-Profile: Yu Wang
Zitieren
APA
Li, H., Dong, Z., Yang, Y., Sun, Q., Lu, F., Li, R., Zhou, W., Gui, W., Gao, R., & Wang, Y. (2025). Decrease of Resolvin D1 and E1 in Patients with Chronic Epilepsy, Implicating Dysfunction of Neuroinflammation Resolution. Journal of Inflammation Research, Volume 18, 8541-8551. https://doi.org/10.2147/jir.s521679
Vancouver
Li H, Dong Z, Yang Y, Sun Q, Lu F, Li R, et al. Decrease of Resolvin D1 and E1 in Patients with Chronic Epilepsy, Implicating Dysfunction of Neuroinflammation Resolution. Journal of Inflammation Research. 2025;Volume 18:8541-8551. doi:10.2147/jir.s521679
BibTeX
@article{Li2025,
author = {Li, Hanli and Dong, Zhong and Yang, Yujing and Sun, Qibing and Lu, Fengqing and Li, Ran and Zhou, Weifeng and Gui, Wei and Gao, Rupan and Wang, Yu},
title = {Decrease of Resolvin D1 and E1 in Patients with Chronic Epilepsy, Implicating Dysfunction of Neuroinflammation Resolution},
journal = {Journal of Inflammation Research},
year = {2025},
volume = {Volume 18},
pages = {8541--8551},
doi = {10.2147/jir.s521679}
}
EUVIMED